ES2948444T3 - Composiciones que comprenden 15-HEPE - Google Patents
Composiciones que comprenden 15-HEPE Download PDFInfo
- Publication number
- ES2948444T3 ES2948444T3 ES16834282T ES16834282T ES2948444T3 ES 2948444 T3 ES2948444 T3 ES 2948444T3 ES 16834282 T ES16834282 T ES 16834282T ES 16834282 T ES16834282 T ES 16834282T ES 2948444 T3 ES2948444 T3 ES 2948444T3
- Authority
- ES
- Spain
- Prior art keywords
- hepe
- approximately
- weight
- composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 title abstract description 92
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 201000010099 disease Diseases 0.000 claims description 21
- 150000002148 esters Chemical class 0.000 claims description 11
- 230000000291 postprandial effect Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- -1 flavorings Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- OWFVSJHRFRIEAK-UHFFFAOYSA-N 15-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCC(O)CCCC=CC=CC=CC=CC=CC(O)=O OWFVSJHRFRIEAK-UHFFFAOYSA-N 0.000 claims description 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 210000001789 adipocyte Anatomy 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 6
- 206010022489 Insulin Resistance Diseases 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 44
- WLKCSMCLEKGITB-DBVSHIMFSA-N 15(S)-HEPE Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-DBVSHIMFSA-N 0.000 description 28
- 208000035475 disorder Diseases 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 8
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 7
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- 230000001174 ascending effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000035558 fertility Effects 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000004626 essential fatty acids Nutrition 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NBGKKXKUONQZME-UHFFFAOYSA-N C(C)OC(C=CC=CC=CC=CC=CCCCC(CCCCC)O)=O Chemical compound C(C)OC(C=CC=CC=CC=CC=CCCCC(CCCCC)O)=O NBGKKXKUONQZME-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 231100000279 safety data Toxicity 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical class 0.000 description 1
- 125000006724 (C1-C5) alkyl ester group Chemical group 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 241001284615 Frangula californica Species 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000004702 methyl esters Chemical group 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269280P | 2015-12-18 | 2015-12-18 | |
| PCT/IB2016/001878 WO2017103671A1 (en) | 2015-12-18 | 2016-12-19 | Compositions comprising 15-hepe and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2948444T3 true ES2948444T3 (es) | 2023-09-12 |
Family
ID=57995240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16834282T Active ES2948444T3 (es) | 2015-12-18 | 2016-12-19 | Composiciones que comprenden 15-HEPE |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9855238B2 (enExample) |
| EP (2) | EP3389647B1 (enExample) |
| JP (4) | JP2018537513A (enExample) |
| KR (6) | KR20220038818A (enExample) |
| CN (2) | CN113230244A (enExample) |
| AR (1) | AR107143A1 (enExample) |
| AU (4) | AU2016370626B2 (enExample) |
| BR (1) | BR122023026625A2 (enExample) |
| CA (2) | CA3008774C (enExample) |
| ES (1) | ES2948444T3 (enExample) |
| IL (3) | IL318963A (enExample) |
| MX (2) | MX394051B (enExample) |
| NZ (1) | NZ744323A (enExample) |
| PH (1) | PH12018501279A1 (enExample) |
| RU (2) | RU2737089C2 (enExample) |
| SG (1) | SG11201805149XA (enExample) |
| WO (1) | WO2017103671A1 (enExample) |
| ZA (2) | ZA201804779B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| US10017453B2 (en) | 2013-11-15 | 2018-07-10 | Ds Biopharma Limited | Pharmaceutically acceptable salts of fatty acids |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| MA47141A (fr) | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| US20170020836A1 (en) | 2015-07-21 | 2017-01-26 | Dignity Sciences Limited | Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease |
| RU2737089C2 (ru) * | 2015-12-18 | 2020-11-24 | Эфиммьюн Лимитед | Композиции, содержащие 15-hepe, и способы их применения |
| CN113116878A (zh) * | 2020-01-10 | 2021-07-16 | 南京大学 | 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| US11622495B2 (en) | 2021-06-01 | 2023-04-11 | Gint Co., Ltd. | Method of automatically combining farm vehicle and work machine and farm vehicle |
| CN113855659B (zh) * | 2021-11-24 | 2022-12-23 | 中国人民解放军东部战区总医院 | 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| AU683027B2 (en) | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
| AU702240B2 (en) | 1993-10-01 | 1999-02-18 | R.P. Scherer Corporation | Methods and compositions for dispensing fragrances |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| EP1762557B1 (en) | 2000-02-16 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| US20020188024A1 (en) | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| CN1268328C (zh) | 2001-05-30 | 2006-08-09 | 拉克斯戴尔有限公司 | 辅酶q与二十碳五烯酸(epa) |
| NZ540154A (en) | 2002-11-22 | 2008-07-31 | Nippon Suisan Kaisha Ltd | External composition containing polyunsaturated fatty acid or its salt or ester |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| US20070105954A1 (en) | 2003-12-31 | 2007-05-10 | Ingennus Limited | Formulation containing a carboxylic acid or an ester thereof |
| WO2005102309A2 (en) | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| CN101043884A (zh) | 2004-07-01 | 2007-09-26 | 谢彭斯眼科研究公司 | 用于治疗眼部疾病和病症的组合物和方法 |
| US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| JP5504405B2 (ja) * | 2005-06-10 | 2014-05-28 | 国立大学法人山口大学 | 血管病予防に効果を有する食品組成物 |
| EP3285072B1 (en) | 2006-08-08 | 2020-04-15 | Metabolon, Inc. | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| US20110105510A1 (en) | 2008-06-17 | 2011-05-05 | Hiroshi Ishikawa | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| JP2010229099A (ja) * | 2009-03-27 | 2010-10-14 | Mochida Pharmaceut Co Ltd | 脂質異常症の改善または治療薬 |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US8618168B2 (en) * | 2009-05-22 | 2013-12-31 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of OMEGA3 fatty acid |
| CA2690488C (en) | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| US10154977B2 (en) | 2011-03-25 | 2018-12-18 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| EP2768496A1 (en) | 2011-10-19 | 2014-08-27 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof |
| AU2012345942A1 (en) | 2011-11-29 | 2014-06-12 | Dignity Sciences Limited | Compositions comprising 20-carbon fatty acids and methods of making and using same |
| LT2800563T (lt) | 2012-01-06 | 2018-10-25 | Omthera Pharmaceuticals Inc. | Laisvos rūgšties formos omega-3 polinesočiųjų riebalų rūgščių dpa praturtintos kompozicijos |
| US20120264705A1 (en) | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| AU2013240427B2 (en) * | 2012-03-30 | 2017-08-03 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
| DK2833740T3 (da) | 2012-04-04 | 2017-01-02 | Pronova Biopharma Norge As | Sammensætninger omfattende omega-3-fedtsyrer og D-vitamin til acne vulgaris og/eller eksem og fremgangsmåder og anvendelser deraf |
| ES2946109T3 (es) * | 2012-05-10 | 2023-07-12 | Solutex Na Llc | Aceites con actividad antiinflamatoria que contienen mediadores pro-resolutivos especializados naturales y sus precursores |
| GB201213484D0 (en) * | 2012-07-30 | 2012-09-12 | Dignity Sciences Ltd | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| KR102275447B1 (ko) * | 2013-07-18 | 2021-07-08 | 모치다 세이야쿠 가부시키가이샤 | ω3 지방산의 자기 유화 조성물 |
| US10017453B2 (en) * | 2013-11-15 | 2018-07-10 | Ds Biopharma Limited | Pharmaceutically acceptable salts of fatty acids |
| AU2015204531B2 (en) * | 2014-01-10 | 2019-11-14 | Afimmune Limited | Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| CN113893240A (zh) * | 2015-01-16 | 2022-01-07 | 艾菲穆恩有限公司 | 包含15-hepe的组合物和其使用方法 |
| MA47141A (fr) * | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| US20170020836A1 (en) * | 2015-07-21 | 2017-01-26 | Dignity Sciences Limited | Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease |
| RU2737089C2 (ru) | 2015-12-18 | 2020-11-24 | Эфиммьюн Лимитед | Композиции, содержащие 15-hepe, и способы их применения |
-
2016
- 2016-12-19 RU RU2018126361A patent/RU2737089C2/ru active
- 2016-12-19 CN CN202110567290.8A patent/CN113230244A/zh active Pending
- 2016-12-19 BR BR122023026625-0A patent/BR122023026625A2/pt not_active Application Discontinuation
- 2016-12-19 EP EP16834282.2A patent/EP3389647B1/en active Active
- 2016-12-19 CN CN201680082030.9A patent/CN108697680A/zh active Pending
- 2016-12-19 US US15/383,889 patent/US9855238B2/en active Active
- 2016-12-19 JP JP2018531629A patent/JP2018537513A/ja active Pending
- 2016-12-19 EP EP23158607.4A patent/EP4218736A3/en active Pending
- 2016-12-19 MX MX2021000773A patent/MX394051B/es unknown
- 2016-12-19 MX MX2018007390A patent/MX379262B/es unknown
- 2016-12-19 KR KR1020227008483A patent/KR20220038818A/ko not_active Ceased
- 2016-12-19 KR KR1020257027779A patent/KR20250130433A/ko active Pending
- 2016-12-19 AU AU2016370626A patent/AU2016370626B2/en active Active
- 2016-12-19 AR ARP160103915A patent/AR107143A1/es not_active Application Discontinuation
- 2016-12-19 IL IL318963A patent/IL318963A/en unknown
- 2016-12-19 KR KR1020187020457A patent/KR20180094516A/ko not_active Ceased
- 2016-12-19 IL IL294736A patent/IL294736A/en unknown
- 2016-12-19 KR KR1020247011532A patent/KR20240052856A/ko not_active Ceased
- 2016-12-19 ES ES16834282T patent/ES2948444T3/es active Active
- 2016-12-19 SG SG11201805149XA patent/SG11201805149XA/en unknown
- 2016-12-19 RU RU2020137883A patent/RU2020137883A/ru unknown
- 2016-12-19 KR KR1020207013456A patent/KR20200055154A/ko not_active Ceased
- 2016-12-19 CA CA3008774A patent/CA3008774C/en active Active
- 2016-12-19 KR KR1020237010220A patent/KR20230047501A/ko not_active Ceased
- 2016-12-19 NZ NZ744323A patent/NZ744323A/en unknown
- 2016-12-19 WO PCT/IB2016/001878 patent/WO2017103671A1/en not_active Ceased
- 2016-12-19 CA CA3129008A patent/CA3129008A1/en active Pending
-
2017
- 2017-12-14 US US15/841,363 patent/US10231945B2/en active Active
-
2018
- 2018-06-06 IL IL259846A patent/IL259846A/en unknown
- 2018-06-14 PH PH12018501279A patent/PH12018501279A1/en unknown
- 2018-07-17 ZA ZA2018/04779A patent/ZA201804779B/en unknown
-
2019
- 2019-01-31 US US16/263,486 patent/US20190224154A1/en not_active Abandoned
- 2019-11-27 JP JP2019214063A patent/JP2020063259A/ja active Pending
-
2020
- 2020-11-11 AU AU2020267224A patent/AU2020267224B2/en active Active
-
2021
- 2021-07-15 ZA ZA2021/04969A patent/ZA202104969B/en unknown
- 2021-07-19 JP JP2021118532A patent/JP2021178840A/ja active Pending
-
2022
- 2022-05-20 US US17/750,262 patent/US12274685B2/en active Active
- 2022-12-23 AU AU2022291628A patent/AU2022291628B2/en active Active
-
2023
- 2023-07-21 JP JP2023118782A patent/JP2023153863A/ja active Pending
-
2025
- 2025-03-05 AU AU2025201593A patent/AU2025201593A1/en active Pending
- 2025-03-19 US US19/083,602 patent/US20250281442A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2948444T3 (es) | Composiciones que comprenden 15-HEPE | |
| CN105120872B (zh) | 包含15-hepe的组合物以及其使用方法 | |
| US20190216761A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| BR112018012313B1 (pt) | Uso de ácido 15-hidroxieicosapentaenoico ou de um derivado farmaceuticamente aceitável do mesmo para inibir ou aliviar uma doença selecionada dentre artrite, doença de huntington, sensibilidade à insulina comprometida, psoríase, câncer de pele, diferenciação de adipócitos, dor e obesidade |